Trials / Completed
CompletedNCT02289196
Safety Study of Vx006 Vaccine in Solid Tumor Patients
A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg, 5mg and 10mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Vaxon Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with histologically proven malignancy with documented disease control (objective response or stable disease) or Not Evaluable Disease (NED) expectancy \> 6 months; only HLA-A\*02 positive patients. The primary objective of the trial is to compare safety and tolerability of four different doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses of the Vx-006.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vx-006: 0,5mg | |
| DRUG | Vx-006: 1mg | |
| DRUG | Vx-006: 5mg | |
| DRUG | Vx-006: 10mg |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-10-01
- Completion
- 2017-05-01
- First posted
- 2014-11-13
- Last updated
- 2019-06-19
Locations
3 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT02289196. Inclusion in this directory is not an endorsement.